The use of testosterone as a male contraceptive (Q33637774)

28 July 2017

1 reference

title

The use of testosterone as a male contraceptive (English)

1 reference

28 July 2017

1 reference

1 reference

J K Amory

1

1 reference

PubMed ID

10332567

28 July 2017

W J Bremner

series ordinal

2

1 reference

28 July 2017

1 October 1998

1 reference

Bailliere's clinical endocrinology and metabolism

28 July 2017

1 reference

28 July 2017

12

1 reference

28 July 2017

3

1 reference

28 July 2017

471-484

1 reference

Attainment and maintenance of azoospermia with combined monthly injections of depot medroxyprogesterone acetate and testosterone enanthate

28 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

Androgens in men--uses and abuses

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

Pregnancies associated with sperm concentrations below 10 million/ml in clinical studies of a potential male contraceptive method, monthly depot medroxyprogesterone acetate and testosterone esters

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

Study of medroxyprogesterone acetate and testosterone enanthate as a male contraceptive

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

The pharmacology and metabolism of testosterone undecanoate (TU), a new orally active androgen

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

Prospects for new hormonal male contraceptives.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

Sperm suppression with monthly injections of medroxyprogesterone acetate combined with testosterone enanthate at a high dose (500 mg)

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

Clinical evaluation of long-term treatment with levo-norgestrel and testosterone enanthate in normal men

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

Clinical trial with levo-norgestrel and testosterone oenanthate for male fertility control

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

The effect of monthly depot medroxyprogesterone acetate and testosterone on human spermatogenesis. I. Uniform dosage levels

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

The effect of monthly depot medroxyprogesterone acetate and testosterone on human spermatogenesis. II. High initial dose

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

Suppression of human spermatogenesis by testosterone implants

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

Factors in nonuniform induction of azoospermia by testosterone enanthate in normal men. World Health Organization Task Force on Methods for the Regulation of Male Fertility.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

Effects of testosterone and dihydrotestosterone on spermatogenesis, rete testis fluid, and peripheral androgen levels in hypophysectomized rats

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

A role for oestrogens in the male reproductive system

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

Combination of 19-nortestosterone-hexyloxyphenylpropionate (Anadur) and depot-medroxyprogesterone-acetate (Clinovir) for male contraception

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

Endocrine control of human spermatogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

Inhibition of spermatogenesis in men with monthly injections of medroxyprogesterone acetate and testosterone enanthate

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

An oral regimen of cyproterone acetate and testosterone undecanoate for spermatogenic suppression in men.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

Testosterone Concentrations in Testes of Normal Men: Effects of Testosterone Propionate Administration

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

Pharmacology of antiandrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

Reversible azoospermia induced by an androgen-progestin combination regimen in Indonesian men

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

Effect of chronic administration of testosterone enanthate on sperm production and plasma testosterone, follicle-stimulating hormone, and luteinizing hormone levels: a preliminary evaluation of a possible male contraceptive

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

Testosterone enanthate a possible reversible male contraceptive

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

Suppression of human spermatogenesis by depot androgen: Potential for male contraception

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-351X%2898%2980229-2

7 January 2021

10.1016/S0950-351X(98)80229-2

Identifiers

DOI

1 reference

28 July 2017

1 reference

PubMed ID

10332567